Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells

• US 8,057,789 B2
• Filed: 10/31/2007
• Issued: 11/15/2011
• Est. Priority Date: 02/13/2002
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): Li; Q. Janice
• Application Number:
  US11/982,007
• Publication Number:
  US 20080131410A1
• Time in Patent Office: 1,476 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/90 : Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2509/00 : Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/90 : Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 : General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The present invention provides compositions and methods of using placental stem cells that originate from a postpartum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

Claims

1. A composition comprising human stem or progenitor cells and a population of isolated CD34⁻

human placental stem cells, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

3. The composition of claim 1, wherein said isolated human stem or progenitor cells comprise CD34⁺ cells.

5. The composition of claim 1, wherein the ratio of said stem or progenitor cells to said placental stem cells is at least 1:

10 by numbers of cells.

6. The composition of claim 1, wherein the ratio of said stem or progenitor cells to said placental stem cells is at least 10:

1 by numbers of cells.

7. The composition of claim 1 or 2 further comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), Fms-like-tyrosine kinase 3 ligand (Flt3L), CD40 ligand (CD40L), interferon-alpha (IFN-α

), tumor necrosis factor alpha (TNF-α

), IFN-γ

, IL-2, IL-6, retinoic acid, basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF-β

1), TGF-β

3, hepatocyte growth factor (HGF), epidermal growth factor (EGF), cardiotropin-1, angiotensinogen, angiotensin I (AI), angiotensin II (AII), or angiotensin type 2 receptor agonist.

8. The composition of claim 1 or 2 that is a pharmaceutical composition.

9. The composition of claim 8 that comprises 50 billion of said placental stem cells.

10. The composition of claim 8, wherein said placental stem cells, or said stem or progenitor cells, are allogeneic to an intended recipient of said composition.

11. The composition of claim 8 that has been stored in a gas-permeable container for between 18 hours and 21 days at approximately 0°

C. to 10°

C.

12. The composition of claim 1 or 2 that is contained in a container.

13. The composition of claim 1 wherein the stem or progenitor cells are stem or progenitor cells from placental blood;

fetal or neonatal hematopoietic stem or progenitor cells;

adult stem cells;

or bone marrow stem or progenitor cells.

14. The composition of claim 13, wherein the stem or progenitor cells are bone marrow stem or progenitor cells.

15. The composition of claim 13 wherein the stem or progenitor cells are fetal or neonatal hematopoietic stem or progenitor cells.

16. The composition of claim 15 wherein the hematopoietic stem or progenitor cells comprise cells that are CD34⁺ and CD38⁻

.

51. The composition of claim 1 wherein the placental stem cells are one or more of CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, or CD45⁻

.

52. The composition of claim 1 wherein the placental stem cells are CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, and CD45⁻

.

2. A composition comprising human umbilical cord blood cells and a population of isolated CD34⁻

human placental stem cells, wherein said placental stem cells are obtained from a placenta that has been drained of cord blood and flushed to remove residual blood.

4. The composition of claim 2, wherein said umbilical cord blood cells comprise CD34⁺ cells.

53. The composition of claim 2 wherein the placental stem cells are one or more of CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, or CD45⁻

.

54. The composition of claim 2 wherein the placental stem cells are CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, and CD45⁻

.

17. A kit comprising (1) CD34⁻

placental stem cells, and (2) either stem or progenitor cells, or umbilical cord blood cells;

wherein the cells of (1) are in a first container and the cells of (2) are in a second container.

18. The kit of claim 17, wherein said first container and said second container are bags.

19. The kit of claim 17, wherein said first container and said second container are syringes.

20. The kit of claim 17 additionally comprising one or more of an apparatus for cell culture, a container comprising a cell culture medium, a container comprising one or more components of a cell culture medium, or an apparatus for use in delivery of the cells.

21. The kit of claim 17 comprising in a separate container one or more of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), Fms-like-tyrosine kinase 3 ligand (Flt3L), CD40 ligand (CD40L), interferon-alpha (IFN-α

), tumor necrosis factor alpha (TNF-α

), IFN-γ

, IL-2, IL-6, retinoic acid, basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF-(β

1), TGF-(β

3, hepatocyte growth factor (HGF), epidermal growth factor (EGF), cardiotropin-1, angiotensinogen, angiotensin I (AI), angiotensin II (AII), or an angiotensin type 2 receptor agonist.

22. A composition comprising human stem or progenitor cells and isolated human CD34⁻

placental stem cells, wherein the placental stem cells have been obtained from a placenta that has been drained of cord blood and flushed to remove residual blood, and wherein said placental stem cells comprise a transgene or foreign nucleic acid.

23. The composition of claim 22, wherein said transgene or foreign nucleic acid encodes a selectable marker.

24. A kit comprising the composition of claim 22.

25. A method of making a pharmaceutical composition, comprising combining a plurality of stem or progenitor cells and a population of CD34⁻

placental stem cells, wherein said placental stem cells have been obtained from a placenta that has been drained of cord blood and perfused to remove residual blood.

26. The method of claim 25, wherein the CD34⁻

placental stem cells are one or more of CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, or CD45⁻

.

27. The method of claim 25, further comprising contacting said stem or progenitor cells or said placental stem cells with a cytokine or growth factor prior to said combining.

28. The method of claim 25, further comprising contacting said stem or progenitor cells or said placental stem cells with a cytokine or growth factor after said combining.

55. The method of claim 25, wherein the CD34⁻

placental stem cells are CD10⁺, CD29⁺, CD44⁺, CD54⁺, CD90⁺, OCT-4⁺, and CD45⁻

.

29. A method of differentiating placental stem cells into neural cells, comprising contacting CD34⁻

placental stem cells with one or more compounds that cause differentiation of the placental stem cells into neural cells, so that the placental stem cells differentiate into neural cells.

30. The method of claim 29, comprising the steps of (1) culturing the placental stem cells in culture medium comprising fetal bovine serum and β

-mercaptoethanol for about 24 hours;

(2) culturing the cells in culture medium and β

-mercaptoethanol, or in culture medium comprising 2% dimethylsulfoxide and butylated hydroxyanisole for a time sufficient for expression of nerve growth factor receptor and neurofilament heavy chain gene expression to be detectable by RT-PCR.

31. A method of differentiating placental stem cells into chondrocytes, comprising contacting CD34⁻

placental stem cells with one or more compounds that cause differentiation of the placental stem cells into chondrocytes, so that the placental stem cells differentiate into chondrocytes.

32. The method of claim 31, comprising the steps of (1) pelleting the placental stem cells;

and (2) contacting the pelleted placental stem cells with medium comprising TGF-β

3 for at least 2-3 days, until production of esoinophilic ground substance or chondrocyte cell morphology are observable, or until expression of collagen 2 and collagen 9 genes are detectable by RT-PCR.

33. A method of differentiating placental stem cells into osteocytes, comprising contacting CD34⁻

placental stem cells with one or more compounds that cause differentiation of the placental stem cells into osteocytes, so that the placental stem cells differentiate into osteocytes.

34. The method of claim 33, comprising the steps of (1) culturing said placental stem cells for 24 hours in culture medium;

(2) culturing the cells in medium comprising dexamethasone, ascorbic acid-2-phosphate and β

-glycerophosphate for 2-3 weeks, or until alkaline phosphatase and osteopontin gene expression is detectable by RT-PCR.

35. A method of differentiating placental stem cells into hepatocytes, comprising contacting CD34⁻

placental stem cells with one or more compounds that cause differentiation of the placental stem cells into hepatocytes, so that the placental stem cells differentiate into hepatocytes.

36. The method of claim 35, comprising the steps of (1) culturing the placental stem cells in medium comprising 20% bovine serum, epidermal growth factor and hepatocyte growth factor for a period of time;

and (2) adding IL-6 to the medium.

37. A method of differentiating placental stem cells into pancreatic cells, comprising contacting CD34⁻

placental stem cells with one or more compounds that cause differentiation of the placental stem cell into pancreatic cells, so that the placental stem cells differentiate into pancreatic cells.

38. The method of claim 37, comprising the steps of culturing cells in medium comprising 20% bovine serum, fibroblast growth factor and transforming growth factor-β

1;

(2) adding conditioned medium from nestin-positive neuronal cell cultures to the medium of step (1) at a ratio of about 1;

1; and

(3) culturing for 14-28 days, or until insulin protein is detectable in the culture medium, or insulin gene expression is detectable by RT-PCR.

39. A method of differentiating placental stem cells into cardiac cells, comprising contacting CD34⁻

placental stem cell with one or more compounds that cause differentiation of the placental stem cells into cardiac cells, so that the placental stem cells differentiate into cardiac cells.

40. The method of claim 39, comprising the steps of (1) culturing the cells in medium comprising (a) 20% bovine serum, retinoic acid, bFGF and TGF-β

1 for about 24 hours, or (b) cardiotropin;

or (2) culturing the placental stem cells in protein-free medium for 5-7 days, followed by contacting the placental stem cells with myocardium extract, wherein said myocardium extract is produced by homogenizing 1 gram myocardium in 1% HEPES buffer comprising 1% cord blood serum, centrifuging the extract, and obtaining the supernatant as myocardium extract;

then, after performing step (1) or step (2), (3) culturing the cells for 10-14 days or until expression of a gene for cardiac actin is detectable by RT-PCR.

41. A method of treating an individual in need of hematopoietic reconstitution, comprising administering to said individual a population of placental stem cells and umbilical cord blood cells, wherein said population of placental stem cells is SH2⁺, SH3⁺, SH4⁺, and wherein said population of placental stem cells is additionally either OCT-4⁺, or SSEA3⁻

and SSEA4⁻

, wherein OCT-4 is octamer binding protein 4.

43. The method of claim 41 or claim 42, wherein said population of placental stem cells is CD10⁺, CD29⁺, CD34⁻

, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH2⁺, SH3⁺, SH4⁺, SSEA3⁻

, SSEA4⁻

, and OCT-4⁺.

44. The method of claim 41 or claim 42, wherein said umbilical cord blood cells are administered to said individual in umbilical cord blood.

45. The method of claim 41 or claim 42, wherein said placental stem cells are contained within placental perfusate.

46. The method of claim 41, wherein said individual has leukemia.

47. The method of claim 41, wherein said individual is receiving chemotherapy at the time of said administration.

48. The method of claim 41, wherein said placental stem cells or said umbilical cord blood cells have been cryopreserved prior to said administering.

49. The method of claim 44, wherein said placental stem cells or said umbilical cord blood have been cryopreserved prior to said administering.

50. The method of claim 41, wherein said placental stem cells and said umbilical cord blood cells have been cryopreserved prior to said administering.

42. A method of treating an individual in need of hematopoietic reconstitution, comprising administering to said individual a population of placental stem cells and umbilical cord blood cells, wherein said population of placental stem cells is CD34⁻

, SSEA3⁻

, SSEA4⁻

, and OCT-4⁺.